Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4794378 | 0.86 | POLB (0.51) | POLBMEN1KMT2ATP53MAPT | |
| SCHEMBL4990827 | 0.86 | POLB (0.51) | POLBMEN1KMT2ATP53MAPT | |
| SCHEMBL4996479 | 0.86 | ENPP2 (0.48) | POLBMEN1KMT2ATP53MAPT | |
| SCHEMBL4726589 | 0.83 | BRD4 (0.53) | POLBTP53MAPTALDH1A1 | |
| SCHEMBL4728007 | 0.81 | HCRTR1 (0.51) | POLBMEN1KMT2ATP53MAPT | |
| SCHEMBL5001911 | 0.78 | POLB (0.64) | POLBTP53TACR1HRH3ALDH1A1 | |
| SCHEMBL5001913 | 0.78 | POLB (0.64) | POLBTP53TACR1HRH3ALDH1A1 | |
| SCHEMBL14092543 | 0.77 | BCHE (0.50) | POLBKMT2ATP53MAPT | |
| SCHEMBL14092555 | 0.77 | BCHE (0.50) | POLBKMT2ATP53MAPT | |
| SCHEMBL4986457 | 0.77 | BCHE (0.50) | POLBKMT2ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | claimed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| US-8071625-B2 | E.g., [(1-(2-aminoacetyl)-4-{N-[(3-fluoro-2-methylphenyl)methyl]carbamoyl}(4-piperidyl))methoxy]-N-(4-ethylphenyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071625-B2 | E.g., [(1-(2-aminoacetyl)-4-{N-[(3-fluoro-2-methylphenyl)methyl]carbamoyl}(4-piperidyl))methoxy]-N-(4-ethylphenyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071625-B2 | E.g., [(1-(2-aminoacetyl)-4-{N-[(3-fluoro-2-methylphenyl)methyl]carbamoyl}(4-piperidyl))methoxy]-N-(4-ethylphenyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | POLB 2180/4885MEN1 665/4885KMT2A 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.